Biomarkers for Preclinical Alzheimer’s Disease

  • Robert Perneczky

Part of the Neuromethods book series (NM, volume 137)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Alzheimer’s Disease as a Societal Challenge

    1. Front Matter
      Pages 1-1
    2. Junfang Xu, Chengxuan Qiu
      Pages 3-13
  3. Diagnostic Concepts

    1. Front Matter
      Pages 43-43
    2. Miguel A. Fernández-Blázquez, Marina Ávila-Villanueva, Miguel Medina
      Pages 45-62
    3. Yaakov Stern, Christian Habeck
      Pages 63-70
    4. Johannes Attems, Kirsty E. McAleese, Lauren Walker
      Pages 71-89
  4. Established Markers of Pathophysiology and Risk

    1. Front Matter
      Pages 91-91
    2. Panagiotis Alexopoulos, Chaido Sirinian
      Pages 93-106
    3. Sven Haller, Davide Zanchi, Cristelle Rodriguez, Panteleimon Giannakopoulos
      Pages 107-117
    4. Peter Häussermann, Thorsten Bartsch, Oliver Granert
      Pages 119-147
    5. Timo Grimmer, Jennifer Grace Perryman
      Pages 149-156
  5. Biomarker Discovery

    1. Front Matter
      Pages 167-167
    2. Amanda J. Heslegrave, Wendy E. Heywood, Kevin M. Mills, Henrik Zetterberg
      Pages 169-177
    3. Robert Perneczky, Panagiotis Alexopoulos
      Pages 179-187
    4. Tom MacGillivray, Sarah McGrory, Tom Pearson, James Cameron
      Pages 199-212
    5. Michel J. Grothe, Ingo Kilimann, Lea Grinberg, Helmut Heinsen, Stefan Teipel
      Pages 213-232
  6. Patient Benefit and Ethical Considerations

    1. Front Matter
      Pages 233-233
    2. Kok Pin Ng, Tharick A. Pascoal, Xiaofeng Li, Pedro Rosa-Neto, Serge Gauthier
      Pages 235-248
    3. Alexander F. Kurz, Nicola T. Lautenschlager
      Pages 249-258
  7. Back Matter
    Pages 271-272

About this book


This volume discusses the importance of imaging, fluid, and genetic biomarkers in detecting the earliest pre-symptomatic stages of Alzheimer’s disease (AD). The chapters in this book are separated into five parts. Part one explores the reasons why we need improved approaches for early detection and diagnosis of AD. Part two describes clinical and research techniques for preclinical AD diagnosis. Part three looks at the current methods in use to diagnose AD and how they can also be used for early detection in healthy older individuals. Parts four and five talk about technological advancements in AD diagnosis and ethical considerations in AD research. In Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory.

Comprehensive and cutting-edge, Biomarkers for Preclinical Alzheimer’s Disease is a valuable resource for individuals interested in the use of biomarker strategies to improve early AD detection. This book will be of great interest to researchers and clinicians from both academia and industry.


Epidemiology imaging biomarkers fluid markers Tau imaging

Editors and affiliations

  • Robert Perneczky
    • 1
  1. 1.Department of Psychiatry and PsychotherapyLudwig-Maximilians-Universität MünchenMunichGermany

Bibliographic information

  • DOI
  • Copyright Information Springer Science+Business Media, LLC 2018
  • Publisher Name Humana Press, New York, NY
  • eBook Packages Springer Protocols
  • Print ISBN 978-1-4939-7673-7
  • Online ISBN 978-1-4939-7674-4
  • Series Print ISSN 0893-2336
  • Series Online ISSN 1940-6045
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals